Nanobiotix S.A. (NBTX) Stock Analysis

Q: What is the NBTX stock price target?

Take-profit $33.98 (+0.2% upside). Prior stop was $31.53.

Q: What are the risks of investing in NBTX?

Target reached (-12.2% upside); Quality below floor (3.4 < 4.0); Target reached (-12.2% upside); Quality below floor (3.4 < 4.0).

Q: Is NBTX overvalued or undervalued?

Nanobiotix S.A. trades at a P/E of N/A (forward 138.5). TrendMatrix value score: 2.2/10. Overall verdict: Sell.

Q: What do analysts say about NBTX?

12 analysts cover NBTX with a consensus score of 4.3/5. Average price target: $34.

Breakout setup

SellVALUE-TRAP 1/5Moderate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Sell if holding. Engine safety override at $33.90: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Below-average business quality; Rich valuation.

$33.90+0.2% A.UpsideScore 5.3/10#54 of 158 Biotechnology

Stop $31.53Target $33.98(resistance)A.R:R -0.8:1

Analyst target$34.20+0.9%5 analysts

$33.98our TP

$33.90price

$34.20mean

$26

$39

Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 152d clear, semi cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Target reached (-12.2% upside)

Quality below floor (3.4 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)138.5

Mkt Cap$1.6B

EV/EBITDA-156.2

Profit Mgn-73.5%

ROE—

Rev Growth—

Beta0.55

DividendNone

Rating analysts12

Quality Signals

Piotroski F4/9

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value2.215%0.33

Quality3.415%0.51

Growth10.015%1.50

Momentum7.310%0.73

Sentiment5.010%0.50

Insider Activity5.410%0.54

Peer Rank2.810%0.28

Technical Setup3.55%0.18

Risk Profile7.45%0.37

Catalyst7.55%0.38

Overall (Σ contributions)5.31

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

0.0

Forward Pe

1.0

Analyst Target

3.0

Peg Ratio

7.1

Forward P/E: 138.5xPEG: 0.99Expensive valuation

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

0.3

Value Rank

0.7

Growth Rank

5.0

Unprofitable operations — net margin -73.5%. Quality floor flags this regardless of sector context.static

Roa

0.0

Net Margin

0.0

Fcf Quality

0.0

Current Ratio

4.3

Piotroski F

4.4

Moat

5.0

Gross Margin

10.0

Cash-burning: FCF -24% of revenueNo competitive moat

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Support Resistance

1.4

Bollinger

1.6

Gap

5.0

52w Position

6.2

GatesA.R:R -0.8=NEGATIVEMomentum 7.3>=5.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 152d clearSEMI CYCLE PEAK CLEARBreakoutSuitability: Aggressive

RSI

64 · Neutral

↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $29.01Resistance $34.67

Price Targets

$32

$34

A.Upside+0.2%

A.R:R-0.8:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Target reached (-12.2% upside)

! Quality below floor (3.4 < 4.0)

! Negative risk/reward — downside exceeds upside

Earnings

4/4 beats

Next Earnings2026-09-29 (152d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is NBTX stock a buy right now?

Sell if holding. Engine safety override at $33.90: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Below-average business quality; Rich valuation. Chart setup: Golden cross, above all MAs, RSI 64, MACD bullish. Prior stop was $31.53. Score 5.3/10, moderate confidence.

What is the NBTX stock price target?

Take-profit target: $33.98 (+0.2% upside). Prior stop was $31.53. Stop-loss: $31.53.

What are the risks of investing in NBTX?

Target reached (-12.2% upside); Quality below floor (3.4 < 4.0).

Is NBTX overvalued or undervalued?

Nanobiotix S.A. trades at a P/E of N/A (forward 138.5). TrendMatrix value score: 2.2/10. Verdict: Sell.

What do analysts say about NBTX?

12 analysts cover NBTX with a consensus score of 4.3/5. Average price target: $34.

What does Nanobiotix S.A. do?Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the...

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.